NCT04140500 2026-03-18
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1/2 Active not recruiting
Clinical Trials
36 trialsNCT06780111 2026-03-10
MK-3475-06E
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06747585 2026-03-03
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Alentis Therapeutics AG
Phase 1/2 Recruiting
NCT05319730 2026-03-02
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT07109726 2026-02-27
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
Phase 1/2 Recruiting
NCT04868877 2026-02-19
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
Phase 1/2 Active not recruiting
NCT05312372 2026-02-17
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
Servier
Phase 1/2 Withdrawn
NCT07405151 2026-02-12
MK-3475-06F
Merck Sharp & Dohme LLC
Phase 1/2 Not yet recruiting
NCT07385001 2026-02-03
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
Tang-Du Hospital
Phase 1/2 Recruiting
NCT07189871 2026-01-15
BetaBart
Radiopharm Theranostics, Ltd
Phase 1/2 Recruiting
NCT07061704 2025-12-08
Oncolytic Virus in Esophageal Squamous Cell Carcinoma
Sichuan University
Phase 1/2 Recruiting
NCT05914116 2025-11-21
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Recruiting
NCT06975410 2025-08-01
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Yuhan Corporation
Phase 1/2 Recruiting
NCT05144698 2025-05-14
RAPA-201 Therapy of Solid Tumors
Rapa Therapeutics LLC
Phase 1/2 Recruiting
NCT05473156 2025-03-26
APT-CUBE
AP Biosciences Inc.
Phase 1/2 Recruiting
NCT06746961 2024-12-24
Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
The First Affiliated Hospital of Zhengzhou University
Phase 1/2 Not yet recruiting
NCT04721223 2024-09-19
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT06173986 2023-12-18
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Shanghai Chest Hospital
Phase 1/2 Recruiting
NCT06010212 2023-08-24
Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2 Not yet recruiting
NCT03888092 2023-03-21
Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification
Sunshine Lake Pharma Co., Ltd.
Phase 1/2 Completed
NCT05541445 2022-09-15
Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Unknown
NCT05394415 2022-05-27
LATE
Jiangsu Cancer Institute & Hospital
Phase 1/2 Unknown
NCT03278626 2022-03-28
Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma
NYU Langone Health
Phase 1/2 Terminated
NCT04506138 2021-12-14
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital
Phase 1/2 Unknown
NCT02915432 2021-12-13
The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT00064259 2021-02-17
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT03817567 2019-01-25
Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma
Sinocelltech Ltd.
Phase 1/2 Unknown
NCT03307941 2017-12-19
ARTEMIS-Eso
Jules Bordet Institute
Phase 1/2 Withdrawn
NCT00544362 2016-05-30
Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery
Federation Francophone de Cancerologie Digestive
Phase 1/2 Completed
NCT00093652 2015-10-06
Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT00425425 2014-05-01
Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer
Technical University of Munich
Phase 1/2 Unknown
NCT01993784 2013-11-25
Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.
Peking University
Phase 1/2 Unknown
NCT00445861 2012-06-11
Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
Swiss Cancer Institute
Phase 1/2 Completed
NCT00002984 2012-05-24
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Completed